SAMHD1

Across TCGA pan-cancer cohorts, SAMHD1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SAMHD1 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SAMHD1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SAMHD1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and COAD are the cancer types where SAMHD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.516	0.296	<.001	66	view →
LUAD	DFS	Median	All	0.778	0.439	.001	19	view →
COAD	DFS	Quartile	All	0.913	1.000	.030	18	view →
HNSC	OS	Median	II,III,IV	0.952	1.000	.016	17	view →
UCEC	OS	Median	All	0.862	0.964	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SAMHD1–PDAC (DFS)

Open the PDAC breakdown →